Eaglet Eye develops innovative medical devices for ophthalmology and has recently developed its first device, the ESP (Eye Surface Profiler). With this high-tech eye-measuring instrument, one is able to examine the eye, allowing for faster, easier, and more precise measurements for contact lenses.
Arnoud Snepvangers (right) and Hans Brassé (left) worked on the foundation of Eaglet Eye since 2011. In 2014, the company introduced the Eye Surface Profiler (EPS) and sold it to its first customers.
Eaglet Eye develops innovative medical devices for ophthalmology and has recently developed its first device aimed at the application of contact lenses. The high-tech eye-measuring instrument, the ESP, is able to examine 20mm of the ocular surface. With more than 250,000 measurement points, one is able to examine the curvature and relief of the eye, allowing for faster, easier, and more precise measurements for contact lenses. A link is created with manufacturers of contact lenses, so that contact lenses can be custom-made for any customer.
The ESP is suitable for the better eye care professionals worldwide who want to provide their patients and customers with the right contact lenses.
Eaglet Eye experienced a year of rapid growth and many challenges: e.g. finding and training the right employees, strategic partners and distributors, establishing brand awareness among opinion leaders, optimizing the production process, and penetrating a number of international markets. The Netherlands is the home market. Eaglet Eye also cooperates with partners in the UK, Germany, Italy, Poland, and Denmark. The company also sold their first ESPs to Asia and the US. Preparations are in progress for a market launch in Japan and South Korea.
The goal is to provide advanced technology and the best products in the contact lenses field for eye care professionals as well as patients and customers.
The Eaglet Eye team consists of ophthalmology professionals who all have the enthusiastic drive and ambition to provide innovative high-tech products that can improve the quality of the eye care. The team is led by Arnoud Snepvangers and Hans Brassé. Both have close contact with many healthcare professionals around the world. This intensive cooperation allows the company to continuously develop software and products solutions.
Why KIKK CAPITAL?
Arnoud: “KIKK Capital (fund: ZIF) invests in high-tech companies at a moment where it can usually be very difficult to attract capital for innovative projects. This early investment may just be the push that is needed to launch an innovative commercial product and is thus an important contribution to the independence of start-ups.”
Added value of KIKK CAPITAL
Arnoud: “A decisive factor in our decision to work with KIKK Capital is that they provide more than just the inflow of capital. KIKK Capital also supports its associates with the knowledge and experience of the shareholders and fund management. KIKK Capital is actively involved with its participations and considers itself partly responsible for the success of each company.”